Indication
Nanoliposomal Irinotecan
1 clinical trial
1 product
Clinical trial
Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in Combination With Cadonilimab for First-Line Treatment of Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma : A Single-arm, Phase II StudyStatus: Recruiting, Estimated PCD: 2026-08-30